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Vaccination against the sexually transmitted Human Papilloma Virus (HPV), a necessary agent for the
development of cervical cancer, has triggered much debate. In Austria, HPV policy turned from “lagging
behind” in 2008 into “Europe's frontrunner” by 2013. Drawing on qualitative research, the article shows
how the vaccine was transformed and made “good enough” over the course of ﬁve years. By means of
tinkering and shifting storylines, policy ofﬁcials and experts disassociated the vaccine from gender,
vaccine manufacturers, and youth sexuality. Ultimately, the HPV vaccine functioned to strengthen the
national immunization program. To this end, preventing an effective problematization of the extant
screening program was essential.
© 2016 The Author. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
In August 2013, the Austrian Minister of Health, Alois St€oger,
announced the introduction of a vaccine against the sexually
transmitted Human Papilloma Virus (HPV), a necessary agent for
the development of cervical cancer. It would be administered to all
9-year old children, making Austria a frontrunner in HPV vaccina-
tion policy, compared to its European counterparts where only girls
were being vaccinated. Yet those countries had adopted the vaccine
ﬁve years earlier, as EU level expert committees had recommended
(ECDC, 2008).
This paper follows a lengthy, and not always public, debate on
HPV vaccination in Austria. We trace how HPV policy turned from
“lagging behind” in 2008 into “Europe's frontrunner” in 2013. In
doing so, we ﬁnd interesting parallels to historical efforts to turn
the Pap test into the “right tool for the job” of cervical cancer
screening (Casper and Clarke, 1998). Having observed the initial
rejection of the vaccine in 2008, we ask: How did the HPV vaccine
become good enough in Austria?
In exploring this process, we draw on in-depth interviews with
policy ofﬁcials, clinical experts, researchers, civic actors, and
members of the pharmaceutical industry (n ¼ 13), documentsLtd. This is an open access article(n ¼ 100þ), and observations at public events (n ¼ 8) pertaining to
vaccination. We present our analysis in three inductively derived
stages of translation (Callon, 1986): problematization, enrollment,
and embedding. Below, we ﬁrst review the existing scholarship and
then lay out our analytical framework.2. Cervical cancer prevention: issues and debates
Cervical cancer is the second most common malignancy and
cause of cancer-related death in women worldwide (Boulet et al.,
2008). In Europe, despite widespread and organized gynecologi-
cal screening programs employing the Pap smear test, named after
its inventor Georgios Nicholas Papanicolaou, cervical cancer re-
mains the 10th most common cause of cancer-related mortality
among women (Boulet et al., 2008). In the late 1990s, medical
research made for global headlines when it concluded that infec-
tion with speciﬁc strains of HPV could cause cervical cancer.
Women in good health largely ﬁght off HPV as well as precursors to
cervical cancer, lesions known as cervical intraepithelial neoplasia
(CIN) 1, 2, and 3, but chronic HPV infection is responsible for over
90% of cervical cancer incidence. In 2006 and 2007, respectively,
two vaccines (Gardasil and Cervarix) were approved by the United
States Food and Drug Administration (FDA) and the European
Medicines Agency (EMA). These vaccines were intended to
immunize girls andwomen against several strains of HPV, targetingunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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and 33), and, in the case of Gardasil, additionally those that cause
genital warts (6 and 11).
The medical research community heralded this breakthrough as
the “ﬁrst vaccine against cancer” (Gericke, 2008), recalling earlier
hopes to “eliminate the need for screening” (Richart, 1995: 1926).
Conversely, critical observers commented on the vaccine as an
uncertain and costly tool that might either sexualize children at an
early age, or medicalize women unnecessarily who might beneﬁt
more from improved Pap-based screening programs.
To be sure, state-sponsored vaccination programs have
frequently triggered political conﬂicts (Colgrove, 2006), be it the
pertussis vaccine (against whooping cough) in the 1970s (Blume,
2006), measles, mumps, rubella (MMR), the vaccine against H1N1
(‘swine ﬂu’), or Hepatitis B. These conﬂicts have typically been ar-
ticulated around notions of risk, excessive government interference
versus personal autonomy and parental control (Reiter et al., 2009;
de Visser and McDonnell, 2008), violations of children's bodies,
public versus individual health, and of deﬁnitions of what it means
to be healthy (Hardon and Blume, 2005). Similarly, vaccination
policies embody tensions between eliminating a disease, on the
one hand, to achieve ‘herd immunity’, and protecting individual
choice, on the other, particularly in what Reich (2014) refers to as
neoliberal cultural frames. The tension between these imperatives
is particularly prone to political mobilization when a condition is
seen as the result of a risky lifestyle (cf. Lupton, 1995: 50ff) and
individual (ir)responsibility. HPV vaccination is a case in point.
In recognition of another central political tension, feminist
scholars and health advocates have viewed the HPV vaccine in
relation to biopolitics, through which women's lives are brought
under medical surveillance (Carpenter and Casper, 2009; Mishra
and Graham, 2012; McKie, 2008) in a moral framework of self-
responsibility and social obligation (Howson, 1999: 401;
Armstrong 2007). Indeed, immunizing young children and adults
against HPV became highly controversial across countries (Wailoo
et al., 2010) and representative of what Mamo and Epstein (2013)
conceptualize as a “pharmaceuticalization of sexual risk”, much
like the associations of gay sex with HIV/AIDS in the 1980s, which
linked sexuality and disease in novel ways.
These new associations and tensions came to question existing
screening and prevention policies. As we shall see, the competing
public health logics of screening and primary prevention and the
related tools e Pap and vaccine e as well as their designated ad-
ministrators came to be central tropes in Austrian HPV policy.
3. Analytical framework and methodology
The review above reveals a need for empirical observations of
HPV policy in the making. The framework developed by Casper and
Clarke (1998) in their study of the emergence of the Pap smear is
helpful for this purpose. They show that, in the 1960s, the Pap
smear did not just emerge as the “right tool for the job” but had to
become “good enough” and embedded in particular social and
material work arrangements (Casper and Clarke, 1998). It had to
satisfy several “social worlds” involved in cervical cancer screening,
including medical professionals, technicians, insurers, and
women's groups. Our framework similarly draws on Timmermans
and Berg's proposal that “technologies are embedded in relations of
other tools, practices, groups, professionals, and patients and it is
through their location in these heterogeneous networks that […]
action is possible in health care” (2003: 104). Methodologically, this
means considering “technology in practice” (Timmermans and
Berg, 2003) and the social worlds (cf. Clarke and Star, 2008) that
technologies enable, contain, reproduce, and embody.
Ontologically, we draw on Science and Technology Studies (STS)and feminist approaches to technology (Wajcman, 2008); we view
technologies as contingent on and inseparable from their social
context (Jasanoff, 2004). We opt for an asymmetrical approach in
our situational analysis (Casper and Clarke, 1998; cf. Hogarth et al.,
2012), in which we choose to focus on the claims and practices of a
range of social agents. This stance enables us to investigate notions
of ‘goodness’ and ‘rightness’ (of time, space, agency, and tools) as
artifacts in their claims. By extending the concept of situation
(Clarke and Fujimara, 1997) to include policy infrastructures e in
our case, the national immunization program (NIP) e we argue
that, when a new technology emerges in a particular context, its
introduction involves tinkering with the very design of the tech-
nology and the infrastructure in which this technology emerges to
make it “good enough”. Borrowing Clarke's and Fujimara's (1997)
terms, we argue that tools, jobs, and rightness are co-constructed
in health policy infrastructures, too, and embedded therein.
We inductively distilled three e in part overlapping - phases of
HPV policy in Austria from our material and conceptualize them as
moments of translation (Callon, 1986). At the stage of problem-
atization, an object moves (or is being moved) towards becoming
indispensable and key agents attempt to deﬁne the nature of the
problem and the roles of other actors to ﬁt the proposed solution. In
the process of enrollment, roles are coordinated, which helps
establish a stable network of alliances. Enrollment is only suc-
cessful, however, if actors impose their will on others. In our case,
the translation entailed problematizing historically contingent
screening infrastructures and their gatekeepers, enrolling social
worlds pertinent to the NIP, and what we term the (ongoing)
embedding of the vaccine, drawing on our analytical argument
above.
STS provides little methodological guidance to account for
successful enrollment or “coproduction” of technologies and social
orders (Jasanoff, 2004). We therefore draw on discourse analysis
and identify “storylines” as key tools for enrollment and embed-
ding: “A storyline guides and shapes a policy process over a period
of time […] it allows actors to develop the story, to change it ac-
cording to new insights or to ﬁll in the blanks over time” (Hajer,
2009). Storylines typically remain reasonably open and do not as
such imply consensus, but function to conceal past dissent. By
identifying storylines, we highlight both conﬂict and its conceal-
ment in vaccine adaptation and adoption.
Our methodological choices and the resultant account must be
understood in context: Whereas coverage of North American HPV
controversies has often relied on pharmaceutical campaigns and
health activism, Austria features a federalist social health insurance
system as the most important source of ﬁnancing. Vaccination in
the NIP is tax-funded and direct advertising of pharmaceutical
products is forbidden. Policymaking can be described as corporatist
and health activism is scarce. In our analysis, we draw, ﬁrst, on
qualitative in-depth interviews (n ¼ 13) with ofﬁcials at the Min-
istry of Health (MoH), members of the pharmaceutical industry,
researchers, clinical experts, feminist health activists, and profes-
sional associations. We employed the snowball method to obtain a
sample of what proved to be a fairly closely-knit policy community.
Upon oral consent of respondents, most interviews were recorded
and subsequently transcribed verbatim. Interviews lasted 75 min
on average. We used individual interview guides in these conver-
sations and analyzed their content for repetitive themes, references
to key events and positioning of other agents. Second, we consulted
pertinent written documentation (n ¼ 100þ), meeting reports, and
press releases issued around key moments, as identiﬁed by inter-
view partners. Third, throughout the study, we attended public
events (n¼ 8) pertinent to the subject matter in order to get a sense
of the elite discourse on health policy and vaccination. These events
proved helpful in identifying potential respondents and allowed us
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HPV policy was referred to (for instance, as a failure or a success).
We also subscribed to newsletters of government agencies and civic
actors, and followed national and international science journalism.
Finally, we subscribed to aweb alert (Google alert) listing the terms
“vaccination” or “HPV” in both English and German, and subscribed
to a digital service (OTS) delivering national press releases con-
taining items with the term “health” or “health policy”.
The analysis of secondary literature, interview transcripts, and
observational notes took the shape of situational and positional
maps (Clarke and Star, 2008). These maps included a range of
diachronic subjects, ranging from cancer research and the cells
obtained fromHenrietta Lacks without consent (L€owy, 2011), to the
HPV vaccine, social-scientiﬁc as well as epidemiological concepts,
and social agents. During the writing up of our analysis, it became
increasingly clear that time was a key aspect, speciﬁcally the ways
in which respondents discussed their agency in terms of anticipa-
tion, surprise, innovation, and rightfulness of (non-)action. There-
fore, we chose to present our empirical narrative in a chronological
fashion.
4. Translating cervical cancer prevention in Austria
4.1. Problematizing screening practices 2006e2008
The HPV vaccine Gardasil was licensed comparatively early in
Austria, notably for girls and boys, in October 2006, against a rather
particular cervical cancer screening infrastructure that warrants
explanation. In Austria, a nation-wide cervical cancer screening
strategy was ﬁrst set up in 1970. Women above the age of 20, or at
the latest two years after commencing sexual activity, are offered
annual screenings, though remarkable variation exists even within
Austria (e.g. Krebshilfe 2014; Hauptverband, 2014). Despite the
early introduction of the program, it has remained ﬂawed due to its
loose and opportunistic character: participation depends on indi-
vidual initiative rather than a national recall system. Estimates
suggest an annual screening participation of around 30%
(Hauptverband, 2007). Its effectiveness is additionally hampered by
variation in the tools used and insufﬁcient communication be-
tween gynecologists, cytologists, and technicians (Rasky, 2006).
This enhances the probability for mishaps, known as “bad smears”.
Intersubjective reading variation and persistent shortcomings in
sensitivity and speciﬁcity further hamper diagnostic validity
(Boulet et al., 2008: 11, 13e15). In Austria, much of quality assur-
ance is left to professional associations, reﬂecting a high degree of
professional autonomy. Moreover, only specialists may perform the
test, quite in contrast to other EU countries, where GPs or
specialized nurses may obtain the smear sample. Despite its ﬂaws,
the professional stakes invested in the Pap test were thus high.
At the same time, the advent of the HPV vaccine was welcomed
with a sense of innovation in gynecology. Prominent gynecologists
reportedly anticipated that the vaccine would “revolutionize gy-
necology […] [and we would] no longer have to worry about the
whole quality assurance question around the Pap test” (Interview
10). Gardasil saw one of the speediest licensing trajectories ever in
Austria: clinical trials by the manufacturer were ended early,
because the vaccine's prophylactic effects had been exceptionally
clear (Interview 10). It is worth noting that, at the Medical Uni-
versity of Vienna, a group of gynecologists and gynecological on-
cologists, as well as dermatologists had been intensively studying
HPV and vaccine effectiveness since 2001, publishing very suc-
cessfully on the subject matter (e.g. Joura et al., 2007, 2012).
The vaccine therefore presented a double-edged sword for those
social worlds invested in reducing, if not preventing, cervical cancer
in Austria: the HPV vaccine appealed to gynecologists and theMoH,particularly the ofﬁcials in charge of vaccination policy at the time.
Yet it also brought about a potential to problematize the national
screening program, particularly its opportunistic character, the lack
of quality assurance, and the fragmented nature of its organization.
Fragmentation, in this context, relates to Austrian federalism.
Despite Austria’s small size, its federal states share competencies
with the federal government in a range of policy areas such as
public health and education. In fact, the NIP is exemplary of this
complexity: Since 1998, the NIP has been jointly funded by federal
states (1/6th), federal government (4/6th), and the social insurers'
federation (1/6th). As a cornerstone of the Austrian public health
system, the NIP is based on equity regardless of income, nationality,
gender, or other categories. Importantly, vaccination is not
mandatory.
The following presents an account of how these issues were
mitigated in the process of adoptinge and, as we shall see, adapting
e the HPV vaccine for the NIP. Following the approval of the vaccine
in 2006, the Minister of Health asked the Supreme Health Council
(Oberste Gesundheitsrat, OSR) to assess the possibility of vaccine
introduction. The OSR is a fairly intransparent and, as we found in
our research, inaccessible committee, that, contrary to some of its
European counterparts such as the German STIKO and the Dutch
Gezondheidsraad, does not publish minutes and extensive reports.
The OSR operates independently of the MoH, but allows the
assignment of in-house Ministry experts. Moreover, the Ministry
features its own vaccination expert committee, which operates “in
close collaboration” with the OSR vaccination committee. This set-
up indicates that feasibility and goodness of ﬁt in the NIP are dis-
cussed at a very early stage. Its recommendations are published
annually.
In September 2007, the OSR issued a recommendation in favor
of including HPV vaccination for girls and boys in the NIP. It was
then up to these experts to convince the Minister at the time,
Andrea Kdolsky, that the vaccine was “good enough”, if not indis-
pensable, for the NIP. Given the comparatively high costs of the HPV
vaccine, and its novel feature as a vaccine against a carcinogenic
virus affecting women primarily e this was the state of knowledge
at the time - the MoH faced a multiplicity of new diagnostic and
therapeutic options, as well as potential conﬂicts. While the key
ofﬁcials formulating policy proposals were in favor of expanding
the NIP with the HPV vaccine (Interview 1, 2), Minister Kdolsky, a
Conservative and a medical doctor herself, expressed skepticism
regarding the usefulness of the vaccine, as it might endanger the
national screening program (BMG, 2007). Cervical cancer incident
rates, the Minister was concerned, might in effect rise, rather than
fall, with the introduction of the vaccine.
While the ECDC (2008; cf. Rafﬂe, 2007) had similarly raised
concerns about possible lower attendance to screening programs as
a result of vaccine introduction, Kdolsky's stance presents a
somewhat idiosyncratic interpretation of these concerns. She
contested the message communicated by medical professionals
and patient associations, such as the Krebshilfe, that “this vaccine
could prevent cancer”, as, in fact, it was the virus that caused cancer,
and the vaccine would protect against the virus, rather than cancer.
But more importantly, she asserted: “Efﬁcacy and safety form top
priorities, and no evidence-based data and long-term studies are
available at this point. We do not know […] the effects of admin-
istering retro-viral, that is, gene-technology based inactive cells”
(BMG, 2007). Against the background of a history of resistance
against genetic modiﬁcations in Austria (Felt, 2013; Prainsack et al.,
2010), Kdolsky's reference to genetic technology carried some
weight in this context and was likely to provoke more criticism
than support for the vaccine.
The inexplicable death of a young girl in October 2007 in Upper
Austria only a fewweeks after her ﬁrst HPV vaccination dose added
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There was a risk that historical skepticism towards vaccination
(particularly against MMR) in sub-communities would gain new
momentum. While empirical data regarding this skepticism is
limited, most respondents refer to it as a given. Notably, in Austria,
anti-vaccination sentiment is not primarily religiously driven, but it
includes views of vaccinations as interventions in the natural
course of childhood, fears of “unnatural” adjuvant substances, such
as aluminum (Interview 1), and, as a recent survey suggests,
widespread beliefs that vaccination may cause allergies (OTS,
2013).
Beyond the safety concerns discussed above, budgetary issues
and the industry's willingness to lower prices formed primary
concerns in the Minister's argumentation against an immediate
adoption of the vaccine (BMG, 2007). This focus on costs and un-
certainty, we propose, may also reﬂect her reservations as a Con-
servative to carry responsibility for a vaccine that touched upon the
taboo subject of youth sexuality. As mentioned above, in Austria,
girls are transitioned to specialist gynecological care for the Pap test
relatively early, as a result of which sexuality is compartmentalized
as a medical specialist matter at a comparatively early stage.
The Minister found herself in an emerging mediatized debate
that could potentially harm two cornerstones of public health:
cervical cancer screening and the NIP. She was to reject the OSR
advice, based on her concerns regarding safety and effectiveness,
but needed additional political support to remain credible and in-
dependent of other social worlds invested in Austrian HPV policy in
the making. In an attempt to depoliticize the emerging debate by
demonstrating objectivity, she commissioned an “independent
economic evaluation” (Interview 11) of the vaccine from a newly
founded research institute for Health Technology Assessment
(HTA). While HTA is common practice in other EU countries' poli-
cymaking, assigning numerical value to, for instance, the number of
lives saved per year by means of a public health intervention, was
comparatively unusual in Austria at the time. Yet it appeared to ﬁt
well with a fairly managerial Minister and her political party, which
tends to prize economic expertise. As a multidisciplinary assess-
ment, but also a form of ‘gating’ practice (Black, 2013), HTA con-
siders aspects such as safety, efﬁcacy, effectiveness, necessity,
economic efﬁciency, social impact, and equity. Commissioned by
the Minister, the HTA reporte the ﬁrst of its kind in Austria - had to
be completed within three months, by the end of 2007, and had to
focus on a purely economic evaluation. The HTA report resulted in
three options (Zechmeister et al., 2007: 17):
Option 1: Improvement of screening, that is, optimization of
preventive measures.
Option 2: Vaccination under improved cost-effectiveness due to
lower vaccination price.
Option 3: Vaccination under current condition, but with a high
risk of uncertainty and high costs.
The Minister of Health ultimately chose option 1. The vaccine
was made available in pharmacies for private purchase (around
600EUR for three doses) but not included in the publicly funded
NIP. Yet as the report has been criticized by many for its simpliﬁ-
cations (Interview 1, 2, 7, 8) and was referred to as a keymoment by
nearly all respondents, it is worth exploring it in some detail. First,
in addition to its exclusively economic focus, the evaluation was
driven by situated local assumptions and conditions, such as poorly
available data on screening effectiveness and vaccine uptake. Sec-
ond, the report only estimated cervical cancer prevention rates,
excluding condyloma and cancers affecting men, such as anal and
penile cancer, as the vaccine had not been studied in men yet.
Neither did the report take into account the effect of the vaccine inpreventing pre-cancerous lesions and costs associated with an in-
crease in miscarriages following their removal in conizations
(Interview 7).
Third, critics have questioned the comparatively high dis-
counting rate used in the assessment (5%, rather than 3%) (Inter-
view 7, 1). This methodological choice, along with a high price
assumption, resulted in comparatively conservative projections of
vaccine effectiveness (10, rather than 20 years) and cost-
effectiveness. As governments purchase vaccines at a signiﬁcantly
lower rate than the ofﬁcial retail price, this was a particularly
sensitive assumption. Finally, neither policy ofﬁcials nor the
commissioned HTA report at the time addressed sexual activity,
which meant leaving out all risks of HPV to both male and female
partners, regardless of their sexual orientation, much like vaccine
developers had done (cf. Fisher and Ronald, 2010). Notwithstanding
the potential ﬂaws in the analysis, we propose that they reﬂect not
so much ‘ﬂawed science’, but local science, and were informed by
an economically oriented ministerial order, limited specialized
expertise, and a single consensus document, which, at the time,
formed the basis for HTA practice in Austria (Walter and Zehetmayr,
2006; cf. Zechmeister et al 2007, fn 58).
Let us return now to the three suggested policy options. Politi-
cally speaking, option 3 was clearly unattractive and not recom-
mended, and potentially appealed to the more general historical
skepticism of vaccination in Austria discussed above. Option 2 was
costly as it would involve negotiating with the bearers of the costs
of the NIP and conceding to other stakeholders' demands. Option 1,
arguably vague, non-speciﬁc, and not immediately costly (neither
ﬁnancially, nor politically) seemed most attractive and would at
once protect the Pap infrastructure and its gatekeepers. In sum, the
report therefore helped stabilize a storyline that still featured
women in need of protection, yet not only against cervical cancer,
but against an uncertain new vaccine.
Feminist critics of the vaccine could relate to option 1 and its
underlying storyline, too, both in their resentment of the medi-
calization of women's bodies and their concerns regarding vaccine
manufacturers' bias (Interview 6). Their concern regarding the
apparent proﬁt-seeking behavior of vaccine manufacturers and the
bias in clinical research sponsored by vaccine manufacturers also
resonated in the tone of media reports at the time (St€ockl, 2010). At
the same time, their suggestion that campaigns exaggerated cer-
vical cancer rates to promote vaccine sales, again excluded men's
health as a public health issue, much as the HTA report had done.
This exclusive focus on women around a shared storyline becomes
visible, for instance, in a lead article written by the head of a
feminist health center (Frauengesundheitszentrum), published in
the HTA research group's newsletter (Groth, 2007). The article calls
into question the long-term effectiveness of the vaccine, its use for
women previously exposed to HPV, and demands the set-up of a
standardized nation-wide vaccination register next to an
improvement of the Pap smear in Austria, instead of adopting the
vaccine.
Against this association of feminist, economic, and safety-
related claims, protecting the status quo was ultimately the safest
option, and the Austrian debate around the HPV vaccine was
virtually closed at the level of public health policy. At the same
time, the short-lived media controversy around HPV brought about
a clearer alliance of proponents of the vaccine: clinical experts and
researchers at Vienna Medical University, individual policy ofﬁcials
at the MoH, and experts at the OSR. While they had to concede to
HPV vaccine critics, and the Minister's decision, at this stage, it was
important to avoid further problematization of either screening or
the NIP. Appeasing earlier criticism, the Austrian social insurers'
federation (Hauptverband der Sozialversicherungstr€ager) thus
launched an evaluation project of the Pap smear
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Rasky et al., 2013). In addition, and quite in line with the political
segmentation and high degree of professional autonomy in Austria,
the Viennese Sickness Fund (WGKK) launched a separate quality
improvement project in collaboration with the Viennese medical
association. Finally, the Austrian Cytology Association launched a
self-monitoring initiative, too.
To conclude, the detailed analysis of the HTA report and the
political context of its production show that the chronic instabilities
of the Pap smear (Singleton, 1998) were indeed re-exposed and
problematizedwith the advent of the HPV vaccine. Yet the early HPV
debate in Austriawas rapidly closed by bringing forward arguments
of cost-effectiveness to thwart a broader debate on the quality of
the existing screening program or the weaknesses of the NIP in this
politically, institutionally and professionally fragmented context.
4.2. Enrollment: remaking the vaccine and its context 2008e2013
Following the Minister's decision not to include the HPV vaccine
in the NIP, the debate seemed virtually closed at the level of federal
health policymaking in Austria. While vaccine developers
continued to tinker with, trace and study the HPV vaccine and its
features, it was making its way into Austria's public health system,
using a different route. First, growing evidence concerning the
carcinogenic nature of various strands of HPV led to studies sug-
gesting promising effectiveness for the prevention of anal cancer,
rates of which had been rising in both women and men who have
sex with men. A multinational trial of Gardasil was conducted in
men, and in the US, the HPV debate began to endorse the notion of
vaccinating boys, too, even if campaigns were by no means as
prominent as they were for girls and women (Epstein, 2010: 72ff).
Furthermore, head and neck squamous cell carcinoma (HNSCC), a
disease largely attributed to environmental exposures, were found
to be preventable by way of vaccinating against some strands of
HPV.
Second, in Austria, regional experiments with subsidizing the
vaccine were initiated in 2007 and 2008 and continued in Lower
Austria, Burgenland, and Vorarlberg, enrolling local support. Third,
the vaccine's supporters e key MoH ofﬁcials, clinical researchers -
regrouped around a new storyline as a means to enroll actors:
“saving lives” and “ﬁghting cancer”, two prominent notions in
contemporary health policy. Encompassing these notions, the
discourse of prevention gained increasing prominence as “the most
important pillar for a sustainable health policy” (BMG, 2013). This
appeal to prevention and a collective future was an effective
storyline to invoke coherence and mutual interests. At the same
time, the persistent feminist critique was positioned as “against the
HPV vaccine” and even “vaccination in general” (Interview 1, 7). In
this way, feminist voices were quelled, and their persistent critique
of the HPV vaccine was presented as irrational, as questioning the
NIP in general, and even as “against their own interest” (Interview
1). This positioning effect continued over the years, and led to
mediatized conﬂicts between clinical researchers calling for
gender-neutral HPV vaccination and public health researchers
skeptical of long-term effectiveness in late 2012. Notably, the latter
shared a key concernwith feminists, namely the call for introducing
harmonized vaccination registers in Austria prior to introducing
any new vaccines. Thus critics of the vaccine were at the same time
critics of the infrastructure in which it was to be embedded, indi-
cating the inseparability of technology and context.
In turn, key policy ofﬁcials in charge of vaccination at the MoH
invested in solidifying this infrastructure to counter further prob-
lematization of the NIP. Now headed by a newMinister, Alois St€oger,
considered generally in favor of HPV vaccination (Interview 1), the
MoH continued to strengthen the NIP by adding two e notably lesscontroversial e vaccines in 2012, against pneumococcal and
meningococcal infections. Another key move was a more visible
construction of the need for the HPV vaccine: Statistical surveil-
lance of HPV infections in Austria continued and began to explicitly
e and equallye refer towomen andmen, and all cancers caused by
HPV (e.g. Statistik Austria 2009, cited in BMG, 2013: 2). This meant
that the vaccine was being disentangled from women's bodies
alone and helped construct a public, rather than gendered need for
the vaccine. Again, from a discursive point of view, the construction
of a collective problem and a solution at once contributed to a
persuasive storyline to enroll a broader range of social worlds.
In addition, ofﬁcials at the MoH formed new collaborative net-
works with pharmaceutical manufacturers in the shared aim to
promote vaccination uptake. Speciﬁcally, members of the industry
coalesced in the new Austrian Association of Vaccine Manufac-
turers (€OVIH), the self-declared aims of which include an “evi-
dence-based political discourse on vaccination” (€OVIH, 2015).
Interestingly, its slogan appeals to a shared responsibility, a recur-
rent theme in vaccination policy, not least in Austria: “Vaccination
means carrying responsibility for the individual and society at
large” (€OVIH/BMG/AGES, 2011). In related networks, a ﬁrst survey
was conducted on parental decisions in Austria regarding vacci-
nation and their concerns, suggesting poor supply of information
regarding vaccines and considerable distrust in them (OTS, 2013).
This type of data collection further contributed to the construction
of the need for a stronger NIP.
At the level of the EU, data continued to be gathered on cervical
cancer and HPV vaccination (ECDC, 2012), continuously listing
Austria as an outlier case in HPV policy. Respondents (Interview 1, 7,
10) anecdotally refer to a sense of embarrassment vis-a-vis EU
counterparts, as well as countries in the Global South that had
successfully launched mass-vaccination. Meanwhile, Vienna-based
researchers continued to investigate vaccine efﬁcacy, publishing
widely and updating policy ofﬁcials. These practices not only
contributed to the construction of a need for the vaccine, but also
helped form the conditions of possibility for its adoption.
Next to campaigns, support for the vaccine was mobilized at
particular events. In October 2012, the MoH gathered Austrian
experts in an exclusive seminar in Vienna, where clinical experts
from the UK presented new data on HPV. This evidence, along with
the simultaneous publication of an important review article
regarding the vaccine's effectiveness (Schiller et al., 2012) meant
that the data gathered was now not only enough, but also good
enough, as it pointed to the usefulness of vaccinating both boys and
girls, thereby transforming it into a less gendered vaccine. This
tinkering helped to depoliticize the vaccine andmade it an easier ﬁt
for the NIP, which historically rests on the principle of equity,
perhaps now even more so under a social democratic Minister.
Furthermore, evidence from Swiss trials revealed that admin-
istering two, rather than three doses, offered sufﬁcient protection,
making the vaccine less of a burden organizationally. Two doses
could be completedmore easily within a school year; therefore, this
presented yet another step in reworking both vaccine and infra-
structure for its institutional embedding. At the same time, the
price of the vaccine had decreased signiﬁcantly, while its prophy-
lactic spectrum had broadened and it had already been licensed for
administration to children as young as 9 years old: between 2007
and 2013, the HPV vaccine had (been) transformed into a vaccine
that was very different from the product introduced in 2006.
In August 2013, in the midst of what is typically a time of the
year without much political news, the Minister of Health, Alois
St€oger, announced: “We have expanded the free children's vacci-
nation program step by step. I am certain that, with the inclusion of
the vaccine against HPV, we will be offering an essential contri-
bution to the health of our children. We will save lives.” (BMG,
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presented the decision as univocal and beneﬁcial to all: the Min-
ister of Health, Alois St€oger, Pamela Rendi-Wagner, director of
public health at the MoH and immunologist by training, and the
President of the patient association Krebshilfe, Paul Sevelda, who
also practices gynecology. The minister announced that the vaccine
e Gardasil e would be offered to children as young as 9 years old.
This enrollment effected that the vaccine could be disassociated
from the Pap test, and from gynecologists and clinical researchers
receiving grants from vaccine manufacturers, who had been sus-
pected to be insufﬁciently objective. It could be placed in the hands
and ofﬁces of a professional group typically considered trust-
worthy: pediatricians. In this way, the ﬁnal step of adaptation was
taken: the vaccine had become desexualized, as pediatric settings
and primary schools are typically not associated with sexuality.
4.3. Embedding the vaccine
The embedding of the vaccine in the NIP, particularly given its
transformation into a gender-neutral prophylactic vaccine, was not
quite as smooth and immediate as the press conference had
insinuated. A ﬁrst potential problem that was elegantly glossed
over is the fact that school doctors are not obliged to e nor insured
fore vaccinating children in federal public schools (Bundesschulen).
This legal aspect is not publicly debated, but nonetheless a political
problem, a respondent recounts (Interview 13), as school head-
masters tend to be informally associated with particular political
views on vaccination, and uptake hence depends on them, too, to a
certain extent. A second issue quickly taken up by critics concerned
the need to vaccinate within a school year to ensure completion
rates, yet this was speedily ﬁxed by postponing the original starting
date and offering vaccination at public vaccination ofﬁces, too, until
a child's 12th birthday. This means that schools, as well as pedia-
tricians, mostly found in private practices, and GPs offer the vac-
cine. Crucially, this also means that direct parental consultation can
be circumvented in school-based vaccination programs. Parents or
caretakers of children under the age of 14 are provided with a brief
health status questionnaire and a consent form. Yet any questions
or concerns children may have regarding HPV and sexual trans-
mission are compartmentalized to a professional pediatric setting,
much like the Pap smear is in gynecological practices. Leaﬂets used
for the required parental information explain a wide spectrum of
possible effects of chronic HPV infections and call for preventing
“all tumors associated with HPV infection” before referring to cer-
vical cancer at all, ensuring gender-neutrality. Furthermore, the
leaﬂet explains that “the disease-related viruses are transmitted by
direct mucousmembrane contact, such as by sexual contact or from
the mother to the child during birth” (BMG, 2015: 1), therefore
backgrounding sexuality as much as possible.
This enrollment and embedding of the vaccine to “save lives”,
rather than only “women's lives”, also came with costs for some
social worlds involved in the translation trajectory: Gynecologists
were largely disassociated fromHPV policy, even though their long-
term involvement in studying the vaccine entailed a high level of
prestige and sense of ownership (Interview 7). Moreover, demands
by critics of earlier attempts to include the vaccine in the NIP,
namely the introduction of national vaccination registers, have not
beenmet: TheMoH continues to rely on estimates calculated by the
federal states in diverse ways, a practice rather unusual for Europe
and not quite in line with the recommendations of the ECDC and
the WHO. By positioning critics e be it feminists, economists, in-
dividual politicians, or public health scholars e as (irrational)
vaccination oppositionists, attention was diverted not only from a
potential debate on youth and sexual health, but, at this stage,
steered away from the weaknesses of the NIP towards the strengthsof the NIP.
We were able to observe this appeal to a shared storyline at a
series of events. Regional “Vaccination Days” have historically
served to educate and update doctors, pharmacists, and students
regarding vaccination, and these were typically co-sponsored by
the pharmaceutical industry. In 2014, however, the ﬁrst “Viennese
Independent Vaccination Day” took place. At the event we attended
in January 2015, presenters and moderators alike emphasized their
independence from the pharmaceutical industry. HPV vaccination
was presented as a great success, and particularly the “gender
neutral” nature of the HPV vaccination program was presented as
an exceptional and progressive feature of the NIP. The fact that,
regarding inclusion in the NIP, Austria was not quite an early
adopter was successfully concealed, and HPV vaccination was
celebrated as a particular success.
We observed another instance of concealment of dissent at an
event hosted by the National Bioethics Commission in April 2014.
The event featured a skillfully staged sequence of talks by ofﬁcials,
foreign bioethicists (suggesting enhanced independence), and even
parents of a deceased son who had passed away from secondary
complications of measles and who had attended an anthroposo-
phist school, which is typically associated with opposition to
vaccination in Austria. Similarly, at a conference organized by the
research platform on Ethical and Legal Aspects of Medicine and,
interestingly, hosted by the Viennese Medical Association in
September 2014, HPV vaccination was articulated as an indis-
pensable element of the NIP, and an expert composition of histor-
ical, legal, and medical presentations helped create an image of the
NIP as an interesting, yet in no way controversial object of policy.
More speciﬁcally, one of the speakers suggested that the case of
vaccination opposition was a hopeless one to tackle, thereby
engaging in the kind of positioning work discussed above:
regarding vaccination, one is either in favor or against it, the latter
being an irrational and marginal position. The recent recommen-
dation by the National Bioethics Commission (Bioethikkommission)
to consider compulsory vaccination for health workers against a
variety of infectious diseases further speaks to the strengthening of
the policy discourse on vaccination (Bioethikkommission, 2015).
In sum, it seems that the initial failure to problematize screening
in favor of (its combination with) primary prevention was a bless-
ing in disguise for policymakers: While initially, the HPV vaccine
seemed a costly, uncertain technology to save women's lives, it ul-
timately helped launch a renewed discourse on vaccination. In the
ongoing embedding of the vaccine, chronic weaknesses of the NIP,
such as divergent vaccination registers, were concealed.
5. Conclusion
The HPV vaccine had to be adapted, in order to become good
enough in Austria. At ﬁrst, the vaccine brought about a problem-
atization of the Pap smear, questioning the rightness of not only this
tool, but the invested jobs, or social worlds (Clarke and Star, 2008)
that risked being shifted from screening to primary prevention. Yet
the vaccine failed to convince as a tool to “save women's lives” e
thus the storyline of its proponents at the time in 2007. In the
second phase of HPV policy, labeled enrollment here, ofﬁcials and
clinical experts tinkered with the vaccine and its policy context and
coordinated new alliances. The vaccine became gender-neutral, and
sexuality was backgrounded by having pediatricians administer the
vaccine. The disenrollment of gynecologists also functioned to
disassociate the vaccine from allegedly biased researchers and
proﬁt-seeking vaccine manufacturers. Third, a new storyline e that
of “protecting children and saving lives” functioned to conceal
previous and persistent dissent that continues to shape the uneasy
embedding of the vaccine against the backdrop of chronic
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infrastructures. The uneasy embedding of the two competing tools
e Pap and HPV vaccine e remains vulnerable to future problem-
atization. For the translation (Callon, 1986) explored here is, of
course, an ongoing process, and much like the Pap smear (Casper
and Clarke, 1998: 276), the HPV vaccine is not particularly right
or wrong, but just good enough.
This study speaks to STS and policy scholarship addressing the
coproduction of tools (Clarke and Fujimara, 1997), technologies,
and social orders (Jasanoff, 2004). Across countries, the introduc-
tion of the vaccine brought up new and old questions of rightness.
Yet in our case, the HPV vaccine did not become a public contro-
versy, but a vehicle to achieve overarching political aims to
strengthen the NIP and to launch a policy discourse on vaccination
that marginalizes opposition. This ﬁnding stands in interesting
contrast to HPV policy in the USA (Epstein, 2010), where the in-
clusion of boys, in fact, re-sexualized the vaccine as it revealed
opportunities to protect gay men against anal cancer. The absence
of this debate in Austria may in part be explained by the exclusion
of men in the feminist and health economic discourses presented
here, and by the absence of gay health advocacy in the present case.
Finally, Austrian policymakers, likely having observed the earlier
HPV controversies in North America, had little interest in publi-
cizing the importance of protecting against anal cancer, given its
“indiscussable” nature (Epstein, 2010).
This case study reveals the need for in-depth research of how
newmedical technologies are made “good enough” across different
political contexts, how these transformative processes vary, and
with what social and material effects. To health policy analysts, our
ﬁndings regarding the solidity of political (infra)structures as well
as the marginalization of civic dissent are particularly relevant and
warrant further comparative analyses (Nathanson, 1996). Finally,
policymakers concerned with low vaccine uptake in Austria may
wish to invest in data collection on vaccine behavior to get a better
understanding of how vaccination policy is tinkered with and
translated across different social worlds, including medical pro-
fessionals and private homes.
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